InvestorsHub Logo
Followers 78
Posts 11422
Boards Moderated 0
Alias Born 04/03/2014

Re: F1ash post# 137191

Friday, 01/12/2018 7:07:30 PM

Friday, January 12, 2018 7:07:30 PM

Post# of 465182
“My guess, (and it is a guess) is that reducing the patient estimates from 300 to 200 was a hint that the next trial will be a Phase 2b properly designed trial to test for efficacy rather than a Phase 2/3. “

Completely agree - with so many AD drugs failing FDA will not take risk of approving anything on limited data/results. They will definitely ask at least one P3 - so co as well may do a very good P2b

In any case we are looking at 2-3-4 year journey
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News